In Silico Technologies for FDA-Regulated Products

This technical report discusses the strategic importance of in silico technologies (ISTs) in accelerating breakthroughs and achieving market leadership for FDA-regulated products. It outlines how ISTs, which include computer-based simulations and computational techniques, can transform human health by enhancing the development and evaluation of medical products, food safety, and digital health technologies. The report emphasizes the need for organizations to adopt ISTs to leverage advancements in data processing, causal modeling, and artificial intelligence. It also highlights the various benefits of ISTs, such as cost-effectiveness, innovation acceleration, and improved safety profiles for products. Furthermore, the paper addresses common myths that hinder the adoption of ISTs and presents a business case for investment in these technologies. The goal is to bridge the gap between technical and business teams, encouraging a comprehensive understanding of ISTs as essential tools for modern product development and regulatory compliance.